Efficacy of anti-T-lymphocyte monoclonal antibody (5G2) therapy for prolongation of canine islet allograft survival.
Brendel
M D
MD
Diabetes Research Institute, University of Miami, Florida 33101.
Schachner
R S
RS
Kong
S S
SS
Qian
T
T
Alejandro
R
R
Mintz
D H
DH
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004285:Dogs; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D007074:Immunoglobulin G / Q000145:classification / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D011169:Portal Vein; D013601:T-Lymphocytes / Q000276:immunology*; D016042:Transplantation, Heterotopic; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine